383 related articles for article (PubMed ID: 16986483)
1. Prolastin aerosol therapy and sputum taurine in cystic fibrosis.
Cantin AM; Berthiaume Y; Cloutier D; Martel M
Clin Invest Med; 2006 Aug; 29(4):201-7. PubMed ID: 16986483
[TBL] [Abstract][Full Text] [Related]
2. Effect of recombinant human DNase on alpha1-proteinase inhibitor function: an experimental approach to the combined clinical use of rhDNase and alpha1-PI in CF patients.
Hansen G; Hoffjan S; Mosler K; Schuster A
Lung; 2001; 179(3):185-94. PubMed ID: 11891608
[TBL] [Abstract][Full Text] [Related]
3. [An alpha 1-antitrypsin aerosol in the treatment of cystic fibrosis].
Ferrer Calvete J; Aznar Lucea J; Morales Marín P; Pereda Pérez A; Llopis Carles R; Ribes Koninckx C; Ferrer González P; Marco Martínez V
An Esp Pediatr; 1996 Feb; 44(2):109-11. PubMed ID: 8830566
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis.
Martin SL; Downey D; Bilton D; Keogan MT; Edgar J; Elborn JS;
Pediatr Pulmonol; 2006 Feb; 41(2):177-83. PubMed ID: 16372352
[TBL] [Abstract][Full Text] [Related]
5. alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients.
Griese M; Latzin P; Kappler M; Weckerle K; Heinzlmaier T; Bernhardt T; Hartl D
Eur Respir J; 2007 Feb; 29(2):240-50. PubMed ID: 17050563
[TBL] [Abstract][Full Text] [Related]
6. Prolastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine release.
Nita I; Hollander C; Westin U; Janciauskiene SM
Respir Res; 2005 Jan; 6(1):12. PubMed ID: 15683545
[TBL] [Abstract][Full Text] [Related]
7. Induced sputum inflammatory measures correlate with lung function in children with cystic fibrosis.
Sagel SD; Sontag MK; Wagener JS; Kapsner RK; Osberg I; Accurso FJ
J Pediatr; 2002 Dec; 141(6):811-7. PubMed ID: 12461498
[TBL] [Abstract][Full Text] [Related]
8. Aerosolized prolastin suppresses bacterial proliferation in a model of chronic Pseudomonas aeruginosa lung infection.
Cantin AM; Woods DE
Am J Respir Crit Care Med; 1999 Oct; 160(4):1130-5. PubMed ID: 10508798
[TBL] [Abstract][Full Text] [Related]
9. Inhaled alpha1-proteinase inhibitor therapy in patients with cystic fibrosis.
Gaggar A; Chen J; Chmiel JF; Dorkin HL; Flume PA; Griffin R; Nichols D; Donaldson SH
J Cyst Fibros; 2016 Mar; 15(2):227-33. PubMed ID: 26321218
[TBL] [Abstract][Full Text] [Related]
10. Variability of markers of inflammation and infection in induced sputum in children with cystic fibrosis.
Ordoñez CL; Kartashov AI; Wohl ME
J Pediatr; 2004 Nov; 145(5):689-92. PubMed ID: 15520781
[TBL] [Abstract][Full Text] [Related]
11. The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation.
Downey DG; Brockbank S; Martin SL; Ennis M; Elborn JS
Pediatr Pulmonol; 2007 Aug; 42(8):729-35. PubMed ID: 17588254
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease.
Moss RB; Mayer-Hamblett N; Wagener J; Daines C; Hale K; Ahrens R; Gibson RL; Anderson P; Retsch-Bogart G; Nasr SZ; Noth I; Waltz D; Zeitlin P; Ramsey B; Starko K
Pediatr Pulmonol; 2005 Mar; 39(3):209-18. PubMed ID: 15573395
[TBL] [Abstract][Full Text] [Related]
13. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor.
McElvaney NG; Nakamura H; Birrer P; Hébert CA; Wong WL; Alphonso M; Baker JB; Catalano MA; Crystal RG
J Clin Invest; 1992 Oct; 90(4):1296-301. PubMed ID: 1357002
[TBL] [Abstract][Full Text] [Related]
14. Alpha 1-proteinase inhibitor abrogates proteolytic and secretagogue activity of cystic fibrosis sputum.
Hansen G; Schuster A; Zubrod C; Wahn V
Respiration; 1995; 62(3):117-24. PubMed ID: 7569330
[TBL] [Abstract][Full Text] [Related]
15. Neutrophil elastase/alpha 1-proteinase inhibitor complex levels decrease in plasma of cystic fibrosis patients during long-term oral beta-carotene supplementation.
Winklhofer-Roob BM; Schlegel-Haueter SE; Khoschsorur G; van't Hof MA; Suter S; Shmerling DH
Pediatr Res; 1996 Jul; 40(1):130-4. PubMed ID: 8798258
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety and effect on biomarkers of AZD9668 in cystic fibrosis.
Elborn JS; Perrett J; Forsman-Semb K; Marks-Konczalik J; Gunawardena K; Entwistle N
Eur Respir J; 2012 Oct; 40(4):969-76. PubMed ID: 22267768
[TBL] [Abstract][Full Text] [Related]
17. The interaction of alpha 1-proteinase inhibitor and tissue kallikrein in controlling allergic ovine airway hyperresponsiveness.
Forteza R; Botvinnikova Y; Ahmed A; Cortes A; Gundel RH; Wanner A; Abraham WM
Am J Respir Crit Care Med; 1996 Jul; 154(1):36-42. PubMed ID: 8680696
[TBL] [Abstract][Full Text] [Related]
18. The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency.
Stockley RA; Bayley DL; Unsal I; Dowson LJ
Am J Respir Crit Care Med; 2002 Jun; 165(11):1494-8. PubMed ID: 12045122
[TBL] [Abstract][Full Text] [Related]
19. Proteinase 3, a potent secretagogue in airways, is present in cystic fibrosis sputum.
Witko-Sarsat V; Halbwachs-Mecarelli L; Schuster A; Nusbaum P; Ueki I; Canteloup S; Lenoir G; Descamps-Latscha B; Nadel JA
Am J Respir Cell Mol Biol; 1999 Apr; 20(4):729-36. PubMed ID: 10101005
[TBL] [Abstract][Full Text] [Related]
20. Induced sputum in cystic fibrosis: within-week reproducibility of inflammatory markers.
Smountas AA; Lands LC; Mohammed SR; Grey V
Clin Biochem; 2004 Nov; 37(11):1031-6. PubMed ID: 15498533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
